← Back to Search

Stem Cell Therapy

Stem Cell Augmentation for Rotator Cuff Tears

N/A
Waitlist Available
Led By Nikhil N Verma, MD
Research Sponsored by Rush University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient is determined to have a full thickness rotator cuff tear (1-3 cm) or partial tear converted to a full-thickness tear on the pre-operative MRI scan or found arthroscopically and is scheduled to undergo surgical repair
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing whether adding stem cells to rotator cuff surgery helps the repair better than surgery alone. 100 patients will be followed for at least a year.

Who is the study for?
This trial is for individuals with a full thickness rotator cuff tear measuring 1-3 cm, or those with partial tears that are treated as full. They must be scheduled for surgery and able to give informed consent. It's not open to those lacking decision-making ability, with subscapularis involvement, needing revision surgery, or having irreparable tears.Check my eligibility
What is being tested?
The study compares standard arthroscopic rotator cuff repair to the same procedure augmented with mesenchymal stem cells (MSCs), which may improve healing and tendon integrity. The trial will randomly assign patients into two groups and track their recovery over at least one year.See study design
What are the potential side effects?
Potential side effects of MSC augmentation could include pain at the injection site, infection risk increase due to additional intervention, immune system reactions against the stem cells, or complications related to tissue regeneration.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a full tear in my rotator cuff or a partial tear that will be treated as a full tear, and I am scheduled for surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
American Shoulder and Elbow Surgeons (ASES) Score
Secondary outcome measures
Functional Outcomes - Shoulder Exam
Magnetic Resonance Imaging (MRI) Scan
Patient Centered Outcomes - Shoulder Survey

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Rotator cuff repair with stem cellsExperimental Treatment2 Interventions
Using clinically accepted methods, subjects will undergo bone marrow aspiration (from hip, proximal humerus or tibia) through a small incision prior to arthroscopy in the group undergoing MSC augmentation. They will then undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique with mesenchymal stem cell augmentation.
Group II: Rotator cuff repair without stem cellsPlacebo Group1 Intervention
Subjects will undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique, without augmentation of mesenchymal stem cells. To maintain patient blinding, all patients will receive a small incision around the site of expected bone marrow aspiration (hip, proximal humerus, or tibia), regardless of whether or not they receive bone marrow.

Find a Location

Who is running the clinical trial?

Rush University Medical CenterLead Sponsor
422 Previous Clinical Trials
163,424 Total Patients Enrolled
Nikhil N Verma, MDPrincipal InvestigatorMidwest Orthopaedics at Rush University
2 Previous Clinical Trials

Media Library

Mesenchymal Stem Cell Augmentation (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02484950 — N/A
Rotator Cuff Tears Research Study Groups: Rotator cuff repair with stem cells, Rotator cuff repair without stem cells
Rotator Cuff Tears Clinical Trial 2023: Mesenchymal Stem Cell Augmentation Highlights & Side Effects. Trial Name: NCT02484950 — N/A
Mesenchymal Stem Cell Augmentation (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02484950 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Might I be able to partake in this clinical investigation?

"To qualify, potential participants must possess lipocalin 1 and be aged between 18-70 years old. This trial is aiming to recruit a total of 100 individuals."

Answered by AI

What is the size of the cohort for this research endeavor?

"Affirmative, according to records on clinicaltrials.gov this patient-seeking trial is still open for enrollment. It first appeared on November 1st 2015 and was recently modified in June of 2022. The study needs 100 recruits from a single medical centre."

Answered by AI

Does this trial encompass those aged sixty-five and above?

"Adhering to the parameters of this clinical trial, any participants must be within a 18-70 age bracket."

Answered by AI

Are new participants being sought for this investigation?

"Affirmative. According to the details presented on clinicaltrials.gov, this research project is actively searching for participants and has been since November 1st 2015; its last update was June 24th 2022. The team need 100 volunteers from one location."

Answered by AI
Recent research and studies
~6 spots leftby Nov 2024